Drug Trial News

RSS

Italy starts human trials of potential COVID-19 vaccine

Rome's Lazzaro Spallanzani Institute, a hospital specializing in infectious diseases will conduct trials on 90 volunteers in the coming weeks, joining a global effort to develop an immune response to the virus.

25 Aug 2020

UH to participate as study site for Pfizer and BioNTech's COVID-19 vaccine

University Hospitals announced today plans to participate as a study site for the Phase 2/3 global study sponsored by Pfizer Inc. and BioNTech SE of an investigational vaccine, BNT162b2, against SARS-CoV-2.

24 Aug 2020

Evaluating the use of sofosbuvir and daclatasvir for treatment of COVID-19

Several new papers in Journal of Antimicrobial Chemotherapy, published by Oxford University Press, suggest successful treatments for COVID-19.

24 Aug 2020

New cancer vaccine is predicted to be more effective in human trials

Jefferson researchers developing a cancer vaccine to prevent recurrences of gastric, pancreatic, esophageal and colon cancers have added a component that would make the vaccine more effective.

24 Aug 2020

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.

18 Aug 2020

Wits University begins South African trial of Novavax COVID-19 vaccine

NVX-CoV2373 is produced by the biotech company, Novavax (Maryland, U.S.A). Novavax is a late-stage biotechnology company that develops next-generation vaccines for serious infectious diseases.

17 Aug 2020

With COVID vaccine trial, rural Oregon clinic steps onto world stage

From the outside, it appears to be just another suburban allergy clinic, a tidy, tan brick-and-cinder-block building set back from a busy highway and across the road from an auto parts store.

17 Aug 2020

PARP inhibitor can successfully treat a subset of advanced prostate cancer patients

Results from an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with a targeted therapy known as rucaparib, resulting in recent FDA approval.

15 Aug 2020

JAK inhibitors or type I interferon shown to reduce mortality in COVID-19

Now, a new study by researchers at Yale University and published on the preprint server medRxiv in August 2020 reports that the use of two drug categories, namely, JAK inhibitors and Type I interferons (IFNs), is associated with a dramatic improvement in mortality in COVID-19.

13 Aug 2020

Combination regimen improves overall survival in certain patients with AML

A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

12 Aug 2020

Researchers recommend inclusion of pregnant and breastfeeding women in COVID-19 vaccine trials

Researchers from the United Kingdom have published their views on the inclusion of pregnant women in clinical trials for vaccines against the novel coronavirus and the related challenges this presents. Their article titled, “Inclusion of pregnant women in COVID-19 vaccine development”, was published yesterday in The Lancet Infectious Diseases.

12 Aug 2020

COMBAT study shows how pancreatic cancer patients can benefit from immunotherapy

Working with an international team of researchers, HonorHealth Research Institute and the Translational Genomics Research Institute, an affiliate of City of Hope, were instrumental in one of the first clinical trials showing how pancreatic cancer patients can benefit from immunotherapy, according to a four-year study published in a premier scientific journal, Nature Medicine.

11 Aug 2020

1st human data for Sinovac's SARS-CoV-2 CoronaVac vaccine is out

A group of Chinese researchers recently conducted a phase 2 clinical trial to further evaluate the immunogenicity and safety of SARS-CoV-2 inactivated vaccine known as CoronaVac. The results are currently available on the medRxiv preprint server and demonstrate that the vaccine is well tolerated and without any notable dose-related safety concerns, which opens the door for phase 3 clinical trial.

11 Aug 2020

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

A recent study by researchers from China, available on the bioRxiv preprint server, shows how stable neutralizing nanobody Nb11-59 might be a promising prophylactic and therapeutic molecule against coronavirus disease (COVID-19) – especially if administered via the inhalatory route.

11 Aug 2020

First clinical trial could become an effective way to deliver chemotherapy to abdominal cancer patients

City of Hope surgical researchers are the first in the nation to open a clinical trial that could one day become an effective way to deliver chemotherapy to abdominal cancer patients who currently have very few treatment options.

11 Aug 2020

COVID-19 Prevention Network announces Phase 3 trials to evaluate monoclonal antibodies

The COVID-19 Prevention Network (CoVPN) today announced two Phase 3 trials to determine whether monoclonal antibodies (mAbs) can prevent SARS-CoV-2, the virus that causes COVID-19.

11 Aug 2020

Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

On Wednesday, August 5, in Dallas, just one day after the initiative was launched by the National Institutes of Health, Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

10 Aug 2020

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

As the coronavirus vaccine race charges on, many of the investigational candidate vaccines are nearing the final stages of human trials. The results of these trials will determine if they will be granted the green light to manufacture and distribute the vaccine to countries across the globe.

10 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Previous
1
...
70
71
72
73
74
75
76
...
1143
Next

Drug Trial News

Italy starts human trials of potential COVID-19 vaccine

UH to participate as study site for Pfizer and BioNTech's COVID-19 vaccine

Evaluating the use of sofosbuvir and daclatasvir for treatment of COVID-19

New cancer vaccine is predicted to be more effective in human trials

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

Wits University begins South African trial of Novavax COVID-19 vaccine

With COVID vaccine trial, rural Oregon clinic steps onto world stage

PARP inhibitor can successfully treat a subset of advanced prostate cancer patients

JAK inhibitors or type I interferon shown to reduce mortality in COVID-19

Combination regimen improves overall survival in certain patients with AML

Researchers recommend inclusion of pregnant and breastfeeding women in COVID-19 vaccine trials

COMBAT study shows how pancreatic cancer patients can benefit from immunotherapy

1st human data for Sinovac's SARS-CoV-2 CoronaVac vaccine is out

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

First clinical trial could become an effective way to deliver chemotherapy to abdominal cancer patients

COVID-19 Prevention Network announces Phase 3 trials to evaluate monoclonal antibodies

Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News